The HARMONi trial showed ivonescimab plus chemotherapy reduced disease progression risk by 48% in patients with EGFR-mutated NSCLC after TKI failure.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/bispecific-antibody-improves-pfs-egfr-mutated-lung-cancer-2025a1000nyr?src=rss
Author :
Publish date : 2025-09-10 18:55:00
Copyright for syndicated content belongs to the linked Source.
